These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 9510041)

  • 1. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.
    Overgaard J; Hansen HS; Overgaard M; Bastholt L; Berthelsen A; Specht L; Lindeløv B; Jørgensen K
    Radiother Oncol; 1998 Feb; 46(2):135-46. PubMed ID: 9510041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85.
    Overgaard J; Sand Hansen H; Lindeløv B; Overgaard M; Jørgensen K; Rasmusson B; Berthelsen A
    Radiother Oncol; 1991; 20 Suppl 1():143-9. PubMed ID: 2020763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the the Danish Head and Neck Cancer Study (DAHNCA) Protocol 5-85.
    Ben-Josef E
    Radiother Oncol; 1998 Sep; 48(3):344-6. PubMed ID: 9925257
    [No Abstract]   [Full Text] [Related]  

  • 4. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
    Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
    Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group.
    Overgaard J; Hoff CM; Hansen HS; Specht L; Overgaard M; Lassen P; Andersen E; Johansen J; Andersen LJ; Evensen JF; Alsner J; Grau C
    Radiother Oncol; 2018 Apr; 127(1):12-19. PubMed ID: 29523409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study.
    Overgaard J; Hansen HS; Andersen AP; Hjelm-Hansen M; Jørgensen K; Sandberg E; Berthelsen A; Hammer R; Pedersen M
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1065-8. PubMed ID: 2649462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
    Metwally MA; Frederiksen KD; Overgaard J
    Acta Oncol; 2014 May; 53(5):654-61. PubMed ID: 24328536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.
    Overgaard J; Hansen HS; Specht L; Overgaard M; Grau C; Andersen E; Bentzen J; Bastholt L; Hansen O; Johansen J; Andersen L; Evensen JF
    Lancet; 2003 Sep; 362(9388):933-40. PubMed ID: 14511925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.
    Alsner J; Sørensen SB; Overgaard J
    Radiother Oncol; 2001 May; 59(2):179-85. PubMed ID: 11325447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot study of nimorazole as a hypoxic-cell sensitizer with the "chart" regimen in head and neck cancer.
    Cottrill CP; Bishop K; Walton MI; Henk JM
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):807-10. PubMed ID: 9845101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial.
    Overgaard J; Eriksen JG; Nordsmark M; Alsner J; Horsman MR;
    Lancet Oncol; 2005 Oct; 6(10):757-64. PubMed ID: 16198981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival.
    Overgaard J; Hansen HS; Jørgensen K; Hjelm Hansen M
    Int J Radiat Oncol Biol Phys; 1986 Apr; 12(4):515-21. PubMed ID: 3700161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative radiation of free jejunal autografts in patients with advanced cancer of the head and neck.
    Cole CJ; Garden AS; Frankenthaler RA; Reece GP; Morrison WH; Ang KK; Peters LJ
    Cancer; 1995 May; 75(9):2356-60. PubMed ID: 7712448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
    Thomson DJ; Slevin NJ; Baines H; Betts G; Bolton S; Evans M; Garcez K; Irlam J; Lee L; Melillo N; Mistry H; More E; Nutting C; Price JM; Schipani S; Sen M; Yang H; West CM;
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):771-782. PubMed ID: 38072326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx.
    Robbins KT; Fontanesi J; Wong FS; Vicario D; Seagren S; Kumar P; Weisman R; Pellitteri P; Thomas JR; Flick P; Palmer R; Weir A; Kerber C; Murry T; Ferguson R; Los G; Orloff L; Howell SB
    Arch Otolaryngol Head Neck Surg; 1996 Aug; 122(8):853-7. PubMed ID: 8703389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
    Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Accelerated hyperfractionated radiotherapy combined with simultaneous chemotherapy in locally advanced pharyngeal and oral carcinomas].
    Stuschke M; Budach V; Dinges S; Jahnke K; Budach W; Heselmann I; Unger A; Stüben G; Sack H
    Strahlenther Onkol; 1994 Dec; 170(12):689-99. PubMed ID: 7817270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of postradiotherapy neck dissection in supraglottic carcinoma.
    Chan AW; Ancukiewicz M; Carballo N; Montgomery W; Wang CC
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):367-75. PubMed ID: 11380223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.